Nagoya City University East Medical Center, Nagoya, Japan.
Br J Haematol. 2024 Nov;205(5):1672-1673. doi: 10.1111/bjh.19763. Epub 2024 Sep 15.
In patients with acute promyelocytic leukaemia (APL), differentiation syndrome (DS) is a life-threatening complication caused by the differentiating effect of all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). Leucocytosis is frequently observed during induction therapy for APL and is intimately associated with the development of DS and its severity. The management of DS is particularly important due to the high likelihood of excellent outcomes for APL patients who successfully complete induction therapy. Commentary on: Cicconi et al. Leukocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukemia predicts for differentiation syndrome and treatment-related complications. Br J Haematol 2024; 205:1727-1733.
在急性早幼粒细胞白血病（APL）患者中，分化综合征（DS）是一种由全反式维甲酸（ATRA）和/或三氧化二砷（ATO）的分化作用引起的危及生命的并发症。在 APL 的诱导治疗期间常观察到白细胞增多，并且与 DS 的发生及其严重程度密切相关。由于成功完成诱导治疗的 APL 患者有很高的获得良好结果的可能性，因此 DS 的治疗尤其重要。评论：Cicconi 等人。急性早幼粒细胞白血病中全反式维甲酸和三氧化二砷诱导治疗期间的白细胞增多预测分化综合征和治疗相关并发症。英国血液学杂志 2024；205：1727-1733。
